This presentation will delve into the origin and evolution of Decentralized Clinical Trials (DCTs). It will also have a particular focus on the impact of COVID-19 and the crucial importance of diversity, equity, and inclusion (DEI) in clinical trial technology.
This webinar aims to provide the following:
- A comprehensive understanding of DCTs
- The impact of COVID-19 on DCTs
- And how DCTs are living up to their promise of promoting greater DEI
Through an exploration of the historical context and drivers behind DCTs, we’ll highlight how these innovative approaches have reshaped the clinical trial landscape. We’ll examine the key advantages which have contributed to the widespread adoption of DCTs.
Furthermore, the webinar will delve into the impact of the COVID-19 pandemic on the acceleration and acceptance of DCTs. We will discuss how the global health crisis compelled the healthcare industry to rapidly embrace remote and decentralized approaches. Lessons learned from this transformative period will be explored.
Lastly, the webinar will cover the vital need to address DEI considerations for DCTs. By examining the historical disparities and barriers faced by underrepresented communities in clinical trials, we’ll emphasize the importance of utilizing technology to promote DEI. We’ll also cover strategies for enhancing participant recruitment and minimizing biases.
By highlighting the potential of DCTs to address DEI challenges in clinical trials, this presentation aims to contribute to ongoing efforts to promote greater DEI in biomedical research and improve the health outcomes of all patient populations.